Project description DEENESFRITPL A blood test for antidepressant medication choice Treatment of major depressive disorder is based on a trial-and-error approach, with patients trying several different medications and often without the desired response. This has a huge socioeconomic impact affecting millions of people who struggle to recover. Funded by the European Innovation Council, the RxMine project introduces a novel platform to assist the search of the best antidepressant for each patient. The process involves the analysis of a patient blood sample to predict the individual response to various medications. It is based on a brain-in-a-dish model that allows high-throughput screening of available drugs and machine learning to identify the most effective choice in a fast and effortless way. Show the project objective Hide the project objective Objective Major depressive disorder affects around 300M people globally and is the second leading cause of disability, with up to 14 years of life lost per patient and an annual burden of up to €170 billion to the EU. Despite numerous available drugs, 75% of patients do not receive adequate treatment, 63% try multiple medications, and a third do not respond after two rounds of treatment. This trial-and-error approach is destructive to patients, time-consuming for physicians and expensive to health care systems. RxMine revolutionizes this process by combining innovative stem cell technology, genetics, neurobiology, high-throughput screening and machine learning to test multiple antidepressants and screen drug effects using a patient-specific brain-in-a-dish model. RxMine identifies the optimal antidepressant for each patient and potentially reduces hospitalizations by 89%, emergency-room visits by 71% and depression related healthcare costs by 40% with savings up to €6,000 per patient per year. Fields of science natural sciencesbiological sciencesneurobiologymedical and health sciencesbasic medicinepharmacology and pharmacypharmaceutical drugsmedical and health sciencesmedical biotechnologycells technologiesstem cellsengineering and technologymedical engineeringmedical laboratory technologylaboratory samples analysisnatural sciencescomputer and information sciencesartificial intelligencemachine learning Programme(s) HORIZON.3.1 - The European Innovation Council (EIC) Main Programme Topic(s) HORIZON-EIC-2022-ACCELERATOROPEN-01 - EIC Accelerator Open Call for proposal HORIZON-EIC-2022-ACCELERATOR-01 See other projects for this call Funding Scheme HORIZON-AG - HORIZON Action Grant Budget-Based Coordinator GENETIKAPLUS LTD Net EU contribution € 2 499 000,00 Address 126 YIGAL ALON STREET 6744332 TEL AVIV Israel See on map SME The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed. Yes Activity type Private for-profit entities (excluding Higher or Secondary Education Establishments) Links Contact the organisation Opens in new window Participation in EU R&I programmes Opens in new window HORIZON collaboration network Opens in new window Total cost € 3 570 000,00
